Literature DB >> 29289969

Health problems in females carriers of premutation in the FMR1 gene.

Małgorzata Zofia Lisik1.   

Abstract

Premutation in the FMR1 gene occur in the general population with an estimated prevalence 1 in 130-260 females and 1 in 250-810 males. Carriers of premutation are at risk of development of spectrum of neurological, psychiatric and immunological disorders in adulthood. Fragile X-associated disease caused by dynamic mutation (expansion of CGG repeats) can be divided into three disorders: FXS - Fragile X syndrome, FXPOI - Fragile X-associated primary ovarian insufficiency, FXTAS -Fragile X-associated tremor/ataxia syndrome, which can be present in few generations of one family. Immuno-mediated disorders are more common in premutation carriers as compared to control group, especially hypothyroidism and fibromyalgia. Although FMR1-associated conditions are not curable, timely diagnosis through genetic testing is important as it can lead to implementation of treatment strategies and behavioral interventions considered to improve symptoms. Knowledge of expanded allele status for females helps them to make more informed reproductive decisions.

Entities:  

Keywords:  FMR1 gene; depression; premutation

Mesh:

Substances:

Year:  2017        PMID: 29289969     DOI: 10.12740/PP/65778

Source DB:  PubMed          Journal:  Psychiatr Pol        ISSN: 0033-2674            Impact factor:   1.657


  2 in total

1.  Molecular analysis of FMR1 gene in a population in Southern Brazil: Comparison of four methods.

Authors:  Cinthia Ramos; Maristela Ocampos; Ingrid Tremel Barbato; Maria da Graça Bicalho; Renato Nisihara
Journal:  Pract Lab Med       Date:  2020-05-06

2.  Fragile X-Associated Disorders in Serbia: Baseline Quantitative and Qualitative Survey of Knowledge, Attitudes and Practices Among Medical Professionals.

Authors:  Dejan B Budimirovic; Smiljana Cvjetkovic; Zoran Bukumiric; Phan Q Duy; Dragana Protic
Journal:  Front Neurosci       Date:  2018-09-21       Impact factor: 4.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.